Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 1/20 | 0.54 |
| ▸ | GABRD | O14764 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215015 | 0.85 | CNR2 (0.71) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL2216224 | 0.84 | KDM4E (0.59) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL15706009 | 0.84 | KDM4E (0.51) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL2215621 | 0.83 | PTGER4 (0.62) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL2214367 | 0.81 | CNR2 (0.66) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL2215561 | 0.81 | CNR2 (0.76) | KDM4ENPSR1CNR2 | |
| SCHEMBL15706010 | 0.81 | KDM4E (0.46) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL2214460 | 0.80 | CNR2 (0.55) | HPGDKDM4EMAPTALDH1A1HSD17B10 | |
| SCHEMBL15706011 | 0.79 | CNR2 (0.54) | HPGDKDM4EMAPTALDH1A1GABRP | |
| SCHEMBL27962862 | 0.79 | GABRG2 (0.65) | HPGDKDM4EMAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | claimed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | claimed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| CN-103880841-A | HDAC (histone deacetylase) inhibitor containing beta- carboline-3-acryl hydrazono as well as preparation method and application thereof | UNIV NANTONG | 2014-06-25 | — | — | CN | disclosed |
| CN-103304564-A | Beta-carboline derivative containing hydroximic acid as well as preparation method and medical application thereof | UNIV NANTONG | 2013-09-18 | — | — | CN | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | HPGD 822/4885KDM4E 2869/4885MAPT 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.